NCT02310412View on ClinicalTrials.gov

A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma

PHASE2CompletedINTERVENTIONAL

Enrollment

14

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

September 30, 2015

Conditions

Healthy

Interventions

BIOLOGICAL

INTERCEPT treated platelets

Sponsors

Lead Sponsor

Cerus Corporation

All Listed Sponsors

lead

Cerus Corporation

INDUSTRY

NCT02310412 - A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma | Biotech Hunter | Biotech Hunter